ESEARCH has shown that insulin reduces ischemic parenchymal damage in both the brain 18, 33 and spinal cord. 30 In global ischemia, a substantial portion of the beneficial effect of insulin appears related to a direct central nervous system effect of insulin. 34 In focal ischemia, the effects of insulin have not been extensively explored and cannot simply be extrapolated from results derived in global ischemia models.
In focal cerebral ischemia, even the effects of high blood glucose levels, which are generally accepted to be deleterious in global ischemia, are not consistent in the literature. Clinical prospective studies 4, 29 have shown a strong negative prognostic association of hyperglycemia with outcome during acute stroke in humans. 7, 25 Nevertheless, this association has been disputed: one report suggesting that hyperglycemia was correlated with survival only in patients with intracerebral hemorrhage, 36 but not with infarction. Whether hyperglycemia is merely a stress response marker of stroke severity 25, 27, 32, 37 or an elevated blood glucose level itself actually determines a harmful effect has also been debated. 4, 7, 19, 29 If blood glucose levels per se have an effect on infarction size, it might be worthwhile to modulate blood glucose levels in the clinical management of ischemic infarction.
Results reported in the experimental literature on blood glucose levels and outcome after focal ischemia are even less uniform than those in the clinical literature. Although most laboratory research supports a negative relationship between hyperglycemia and outcome after acute focal ischemia, [8] [9] [10] 12, 21, 28, 35, 38 four experimental studies have shown a beneficial effect of preischemic hyperglycemia on focal cerebral infarction. 13, 17, 22, 39 These latter studies all used models of permanent focal vascular occlusion. The literature thus suggests an overall difference between transient and permanent focal ischemia. Transient ischemia appears to incur more damage with high glucose levels, but permanent ischemia seems immune to the harmful effect of hyperglycemia or possibly even benefits from it.
The issue of optimum glycemia in focal cerebral ischemia is of some clinical importance because of the possibility of manipulating blood glucose levels in clinical situations in which transient focal ischemia can be anticipated, such as during carotid endarterectomy or aneurysm clipping. Therefore, we undertook this study in transient ߜ Insulin has recently been shown to ameliorate damage in models of global brain ischemia. To determine whether insulin is also neuroprotective in focal ischemia, 20 rats were given 2 to 3 IU/kg insulin and 10 did not receive treatment prior to normothermic transient middle cerebral artery occlusion for 2 hours at a blood pressure of 60 mm Hg. To further elucidate whether infarction volume is influenced by variations in blood glucose levels within the physiological range, blood glucose was raised in 10 of the insulin-treated animals to levels comparable with the untreated controls. At 1-week survival, damage was assessed using quantitative neuropathological examination of 25 coronal planes. It was found that preischemic insulin lowered the mean intraischemic blood glucose level from 8.4 Ϯ 0.2 mM ( Ϯ standard error of the mean) in the control group to 3.4 Ϯ 0.2 mM and reduced total damage (atrophy plus cortical and striatal necrosis), expressed as the percentage of the normal hemisphere, from a control of 28.5% Ϯ 2.9% to 14.5% Ϯ 1.6% (p Ͻ 0.005). Coadministration of glucose and insulin resulted in a mean intraischemic blood glucose level of 10.1 Ϯ 0.5 mM, with 27.0% Ϯ 2.4% total damage (p = 0.96, compared with control). Total ischemic damage showed an independent correlation with blood glucose levels (r = 0.67, p = 0.0018).
The findings indicate that insulin benefits transient focal ischemia and that reducing the blood glucose from 8 to 9 mM to the low-normal range of 3 to 4 mM with insulin dramatically reduces subsequent infarction. The data suggest that the neuroprotective mechanism of insulin action in focal middle cerebral artery occlusion is mediated predominantly via alterations in blood glucose levels. In comparison to global ischemia, focal ischemia appears to show only a minor direct central nervous system effect of insulin. In clinical situations in which transient focal ischemia to the hemisphere can be anticipated, insulin-induced hypoglycemia of a mild degree may be beneficial.
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R focal ischemia to determine whether insulin can reduce infarction volume. Because of the potential therapeutic significance of the use of insulin and the opportunity to mimic clinical situations, blood glucose levels were manipulated only within the physiological range. Giving glucose with insulin in some animals would enable determination of the kind of mechanism involved; any benefit accruing from a mechanism involving hypoglycemia would be annulled by concurrent administration of glucose, whereas a direct beneficial effect of insulin would persist in the absence of hypoglycemia.
Materials and Methods

Animal Preparation
Thirty male Sprague-Dawley rats, each weighing between 378 and 496 g, were used in this study. Anesthesia was induced with 3% halothane in a mixture of 50% O 2 and 50% N 2 O, in rats that had been allowed free access to rat chow and water before surgery. The rats were intubated with P-205 polyethylene tubing* passed over a guide wire inserted between the vocal cords. The animals were then ventilated with 1% halothane using a Starling-type ventilator and given atropine, 0.06 mg intramuscularly, to reduce respiratory secretion.
The ventral tail artery was cannulated with P-50 polyethylene tubing and connected to a transducer. † Blood pressure was automatically recorded by computer every 5 seconds. The lateral tail vein was cannulated with P-50 polyethylene tubing and connected to an infusion of 0.9% normal saline run at 4 ml/kg/hour. The blood glucose, pH, PCO 2 , PO 2 , and hematocrit levels were monitored via the arterial line. Blood glucose was measured using glucose oxidase reagent strips and a reflectance glucometer. Core temperature was monitored and maintained at 37.5˚C Ϯ 0.5˚C using a thermistorregulated servo-controlled heating blanket. Ipsilateral temporalis muscle temperature was monitored throughout the time of the ischemic injury and was maintained at 37.0˚C Ϯ 0.1˚C using an overhead lamp.
The animals were secured in a headholder and the proximal left middle cerebral artery (MCA) was exposed through a 8-to 9-mm diameter subtemporal craniectomy. Additional exposure was obtained by a 1.0-to 1.5-cm vertical incision in the temporalis muscle, removal of the zygoma, and reflection of the temporalis muscle and the trigeminal nerves from the temporal bone. The exposure was maintained using two self-retaining retractors; constant irrigation of warm saline was used to obviate focal hypothermia. A pneumatic drill with a diamond drill bit was used for the craniectomy, and the exposure anterior and inferior to the foramen ovale was enlarged with a microrongeur.
To reduce the variability of the infarction size in all animals, the mean arterial blood pressure was reduced to 60 mm Hg by increasing the halothane concentration to 1.75% to 2.25%. The MCA, clearly visible through the dura, was then occluded in two locations with 10-0 monofilament nylon suture, according to the method of Cole, et al. 6 The dura was left intact during the occlusion process, to avoid atmospheric exposure of the brain and artery. The location of the first MCA occlusion was just proximal to the origin of the lenticulostriate branches, and the second occlusion was at the level of the inferior cerebral vein.
The temporalis muscle temperature was quickly brought to 37˚C if it had fallen during the craniectomy, the animal was removed from the headholder, and the craniectomy site was covered with a small pool of saline for the duration of the experiment. Arterial blood gases and blood glucose level were measured immediately and throughout the ischemic period, and the hematocrit was determined at the end of the ischemic period.
After 2 hours of MCA ischemia, the sutures were cut and removed, the blood pressure was returned to normal, and reperfusion of the MCA was confirmed by direct visual observation. The operative site was covered with Gelfoam and the wound was closed in anatomical layers (temporalis muscle and skin) using 4-0 silk suture. The animals were monitored for a further 15 to 20 minutes to ensure that all physiological parameters had stabilized, the arterial and venous lines were then removed, and the access wound sutured with 4-0 silk. The tip of the tail was cut to allow access to venous blood in the postoperative period for blood glucose measurement. The rats were then allowed to awaken from the anesthesia.
All animals had free access to food and water in the postoperative period. Blood glucose levels were recorded 2 hours after the operation and at least four times thereafter for the first 24 hours. In addition, the weight and Bederson neurological grade 2 were determined at 2 and 6 hours of recovery, and on the 1st and 7th postoperative days. The Bederson neurological grading scheme for focal ischemia in the rat can be briefly summarized: Grade 0 is a normal examination, Grade 1 represents a minimal deficit, and Grades 2 and 3 describe moderate and severe hemiplegia, respectively.
Insulin and Glucose Administration
The insulin used consisted of porcine/bovine crystalline zinc insulin (CZI) and longer acting zinc insulin suspension (Lente) ‡ in the ratios described below. The rats were randomly allocated to three groups. To distinguish any effect of insulin-induced hypoglycemia from that of insulin alone, glucose was given to one group of insulin-treated rats as follows: 10 rats in Group 1 (control) were left untreated. The 10 rats in Group 2 (insulin with moderate hypoglycemia) were treated with insulin only and were allowed to become moderately hypoglycemic (blood glucose 3 to 4 mM). The rats in Group 2 received 2.0 to 2.5 IU/kg insulin in a ratio of 1:2 CZI/Lente intraperitoneally 50 to 70 minutes prior to the onset of ischemia. We established this dose of insulin as optimum for reduction of nonfasting sugar to the defined levels during preexperimental trials. Additional soluble insulin (CZI) was administered, if needed, during the operative procedure to maintain the blood glucose levels in the range of 3 to 4 mM. During the first 24 hours of recovery, blood glucose concentrations were maintained within this range with intraperitoneal injections of insulin as needed.
The 10 animals in Group 3 (insulin plus glucose with normoglycemia) were treated with insulin, but hypoglycemia was prevented by concurrent glucose administration. The rats in Groups 3 received 3 IU/kg insulin in a ratio of 1:2 CZI/Lente intraperitoneally 50 to 70 minutes prior to the onset of ischemia. Immediately after the insulin was administered, the animals received 2 to 4 g/kg of 50% glucose intraperitoneally, and their drinking water was supplemented with 25% glucose to reduce the fluctuations in blood glucose levels while receiving insulin. Blood glucose levels were further regulated to the 5-to 10-mM range over the postischemic period as follows. During the first 24 hours of recovery, the animals were given twice daily intraperitoneal injections of 2 IU/kg Lente insulin and supplemental intraperitoneal glucose injections to maintain blood glucose levels in the range of 5 to 10 mM. This dose of insulin was selected to be similar to that used in Group 2, and because of its demonstrated efficacy in our laboratory in global cerebral ischemia. 33 
Analysis of Hemispheric Damage
The rats in all groups were allowed to survive for 1 week after the operation. The animals were then given 2% halothane anesthesia and killed by means of transcardiac perfusion performed for 30 seconds with saline, followed by 4% formaldehyde, phosphatebuffered to pH 7.30.
The brains were removed and cut coronally into 3-mm slices. After processing, embedding in paraffin, and serial sectioning at 6-m thickness, slides of the brain were made at 250-m intervals and stained with hematoxylin and eosin. Sections encompassing the entire infarction, spaced 500-m apart, were analyzed and referenced to the interaural line. 26 On each of these sections, the areas of each hemisphere and of infarcted cortex and striatum were traced by an observer (M.H.), blind to the treatment received by each rat, using a microscope and an image analysis system.
It was apparent from the differences in the areas of the ipsilateral and contralateral hemispheres (Fig. 1) that atrophy of the ischemic hemisphere had already occurred by 1 week. To measure this tissue loss, probably related mainly to necrotic tissue removal by macrophages, the total areas of the ischemic and nonischemic hemispheres were measured. Atrophy was calculated by subtracting the area of the ischemic hemisphere, including the areas of necrosis, from the nonischemic hemisphere.
Volumes of cortical necrosis, striatal necrosis, and atrophy were then determined using a three-dimensional reconstruction program, § which integrated all x-y area measurements in the third dimension to calculate the damage volumes, taking into account the alignment of the sections along a reference point (the center of the corpus callosum). The percentage of hemispheric damage was calculated by adding tissue loss due to atrophy to that due to necrosis and dividing these by the area of the contralateral hemisphere.
Physiological parameters were assumed to be parametric variables and were compared using one-way analysis of variance (ANOVA), with Scheffé's test for multiple comparison between groups. One-way ANOVA with Scheffé's test was also used to compare the areas of necrosis and atrophy at all coronal planes and to compare the damage volumes. The Kruskal-Wallis test was used to compare the Bederson neurological grades. Finally, linear regression analysis was completed to determine the contribution of the preischemic, intraischemic, postischemic, and mean preischemic blood sugars to damage volume. Differences were considered to be significant at the p Ͻ 0.05 level. All statistical calculations were performed using a commercially available program.
Results
The rats receiving only insulin had lower blood glucose levels than either the controls or animals receiving insulin and glucose (Table 1) , before, during, and for the 24 hours after the 2-hour ischemic episode. Intraischemic blood glucose levels in the insulin-treated group fell within the low but physiological range (3.4 Ϯ 0.2 mM). Animals treated with glucose plus insulin had intraischemic glucose levels that were higher than the controls by 1.7 mM. There were no significant differences between groups in the remaining physiological parameters, except for a lower intraischemic pH and a higher PO 2 in Group 3 ( Table 2 ).
All 30 rats survived 1 week. Insulin improved their clinical restitution after ischemia. Group 2 rats treated with insulin but not glucose showed a substantial improvement in the Bederson neurological rating scale (Fig. 2) at both 6 hours (p Ͻ 0.05) and 24 hours (p Ͻ 0.005). By 7 days of recovery (data not shown), the median score in all groups had returned to zero.
One Group 1 brain was damaged during histological processing, and it was necessary to exclude one Group 2 rat from the analysis due to a large cerebral abscess. Untreated animals had a cortical infarct volume of 39.9 Ϯ 7.3 mm . Although mean infarct areas were less in both treated groups at all coronal levels examined, these volume differences (Fig. 3) were not significant.
In the striatum, insulin alone reduced the volume of striatal necrosis in the animals from 19.3 Ϯ 3.8 mm 3 to 6.8 Ϯ . A representative section illustrating the hemispheric atrophy is shown (Fig. 1) .
The sum of cortical necrosis, striatal necrosis, and hemispheric atrophy was 113.6 Ϯ 17.8 mm 3 in untreated animals (Fig. 5) . Insulin with moderate hypoglycemia reduced total damage to 51.9 Ϯ 7.7 mm 3 (p Ͻ 0.05). The insulin/normoglycemia group showed an insignificant reduction from control group, with a total damage volume of 96.5 Ϯ 12.5 mm 3 . When total damage was expressed as the percentage of the normal hemisphere, insulin with moderate hypoglycemia reduced damage from a control of 28.5% Ϯ 2.9% to 14.5% Ϯ 1.6% of the hemisphere (p Ͻ 0.005). Coadministration of glucose and insulin resulted in no significant change from untreated animals, with 27.0% Ϯ 2.4% damage within the hemisphere between bregma Ϫ2.2 mm and bregma Ϫ14.7 mm.
To further investigate the mechanism of insulin action in focal ischemia, specifically the importance of blood glucose levels, regression analyses were done to define the relationship of the blood glucose levels to the total volume of cerebral damage. Because our previous data in transient global ischemia 34 indicated that insulin acts at least partly via a direct effect on the central nervous system, it was necessary to control for the presence or absence of insulin in such analyses. Thus, only animals receiving insulin (Groups 2 and 3) were included. The strongest relationship (Fig. 6 ) was between the mean preischemic blood glucose and the total damage volume (r = 0.67, p = 0.0018), although there was also a correlation between the intraischemic blood glucose level and the total damage volume (r = 0.66, p = 0.0021).
Discussion
This study demonstrates that insulin pretreatment mitigates cerebral infarction due to transient focal ischemia, augmenting the conclusions from models of transient global cerebral ischemia. 18, 33, 34 Furthermore, lowering blood glucose levels, even within the physiological range, FIG. 2. Pie charts depicting neurological scores at 6 hours and at 1 day, according to the rating scale of Bederson, et al. 2 At 6 hours of recovery, insulin-treated rats showed better neurological scores than rats treated with insulin and glucose (p = 0.0247), and scores were also better than in untreated animals (p = 0.0193). At 24 hours of recovery, insulin-treated rats still showed better neurological scores than rats treated with insulin and glucose (p = 0.0025), and again scores were better than in untreated animals (p = 0.0041). No significant differences were seen at any recovery interval between the clinical neurological scores of rats treated with insulin plus glucose and untreated animals.
modulates the size of the resulting MCA infarction. Insulin with mild hypoglycemia reduced cortical infarction, with no increase in mortality. The reduction in damage volume was in fact associated with a significant improvement in the neurological restitution. This effect was seen by lowering blood glucose within the physiological range.
One study reduced blood glucose levels with insulin outside the physiological range to 2.0 mM and demonstrated a reduction in infarction size compared to animals having a blood glucose level of 28 mM. 23 Other researchers claimed a beneficial effect from both fasting and insulin treatment; 38 however, no consistent effect of blood glucose levels on infarction size was shown, and infarction volumes were 99 Ϯ 26 mm 3 (mean Ϯ standard error of the mean) at less than 60 mg/dl, 9 Ϯ 6 mm 3 at 60 to 180 mg/dl, and 112 Ϯ 36 mm 3 at more than 180 mg/dl blood glucose levels. Izumi and colleagues 15 recently discussed the possibility of a direct neuroprotective role of insulin in focal MCA occlusion, but blood glucose levels were not a controlled variable and were occasionally, but not always, different from controls. In addition, the insulin-treated animals had a lower body temperature (up to 0.9˚C) than untreated controls. After transient global ischemia, insulin has been shown to have a direct central nervous system effect in reducing cerebral necrosis. 34 The results in this study suggest that such a direct effect, if it exists, is far less important in transient focal ischemia.
Many experimental studies examining the role of glycemia during focal cerebral ischemia have used extremely high blood glucose levels, probably seen clinically only in diabetic patients. Such high blood glucose levels undoubtedly exacerbate the detrimental ischemiainduced lactic acidosis and can also worsen cerebral blood flow. 11, 14 However, in our study, hyperglycemia was minimal. Blood flow was shown to be reduced by only 7% per 10 mM increase in blood glucose in nonischemic animals; 11 thus, the mechanism of glucose modulation of ischemic damage likely involves metabolic, not blood flow effects, which supports the conclusions of others. 24 This metabolic mechanism may involve mitigation of intraischemic acidosis by preischemic hypoglycemia, as shown in global ischemia. 5 The suggestion that the beneficial effect of altering blood glucose levels occurs by a mechanism altering metabolism, not blood flow, is further supported by recent findings in our laboratory that demonstrate a significant effect of blood glucose in modulating the volume of damage induced purely by the intracerebral injection of excitatory amino acid agonists (our unpublished data). Because excitatory amino acids may play a significant role in the pathogenesis of ischemic damage, this excitatory mechanism, being glucose sensitive, may be a pathophysiological component explaining the effect of glucose on ischemic damage.
The finding of a less prominent component of direct insulin action in focal as opposed to global ischemia warrants an explanation. Transient global ischemia is characterized by reperfusion after much shorter ischemic periods than focal ischemia producing infarction. Furthermore, it is accompanied by delayed neuronal death, 16 during which time insulin might act centrally in the reperfusion period to salvage neurons. Transient focal ischemia, in contrast, involves arterial occlusion and thereby attenuates direct access of insulin to the core of the ischemic territory; transient focal ischemia is also tolerable for longer periods than global ischemia. 
Conclusions
This experimental data may have major application in the management of human focal cerebral ischemia when pretreatment is possible. These findings have possible relevance to clinical situations involving transient MCA occlusion such as thromboembolism, but they could also be directly applied in neurosurgical procedures that require temporary occlusion of cerebral vessels, such as carotid endarterectomy, or clipping of cerebral aneurysms. In considering the clinical use of insulin, only moderate hypoglycemia (range 3 to 4 mM) should be employed to obviate the biochemical and neuropathological consequences of profound hypoglycemia on the brain. 31 Blood glucose levels in the range of 3 to 4 mM or lower appear to be very well tolerated in humans with focal MCA occlusions. 20 Reversible focal neurological deficits may occur, but these relate to reversible physiological inhibition in tissue function due to an altered energy state, unaccompanied by permanent changes in tissue structure. 1, 20 Mild hypoglycemia in the low-normal range of blood glucose levels may thus be therapeutically considered to obviate structural ischemic brain damage caused by temporary arterial occlusion. To control for the presence or absence of insulin, only rats in the two groups that had received insulin in identical doses (Table  2 ) are analyzed. Over the range of physiological blood glucose values, a significant contribution to the tissue-loss damage is seen with increasing blood glucose concentrations.
